Author

Miguel Gaspar

AstraZeneca (United Kingdom)Primary ORCID profile (0000-0001-9237-6934 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Miguel GaspariD3 papers · Champalimaud Foundation

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andrew David BeggsiD· 1 shared Charlotte Blanc· 1 shared Claudia Maria Assunta PinnaiD· 1 shared David G. MillariD· 1 shared Elsa Rottoli· 1 shared Jing ZhangiD· 1 shared Kaitlin A. Marley· 1 shared Kamila Rakhimova· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew David BeggsORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A low-matrix organoid-T cell co-culture platform for functional evaluation of T cell engagers in patient-derived colorectal cancer organoids

Claudia Maria Assunta Pinna, Kamila Rakhimova, Jing Zhang, Laura Bills, Louise Tee, Charlotte Blanc, David G. Millar, Elsa Rottoli, Oisín Huhn, Miguel Gaspar, Neeraj Lal, Romain Lara, Kaitlin A. Marley, Sašo Čemerski, Simon J. Dovedi, Andrew David Beggs

This paper develops a low-matrix co-culture platform to evaluate T cell engager activity in patient-derived CRC organoids, showing dose-dependent cytotoxicity and immune activation across diverse models.

bioRxiv · Sep 27, 2026 · PreprintCancer Biology